Almac provides research, development and delivery of pharmaceutical services worldwide.
The company offers a large range of integrated contract pharmaceutical development and manufacturing services ranging from research to commercialisation.
Almac specialises in a wide range of pharmaceutical services, from diagnostics and pre-clinical biomarker discovery to companion diagnostic development and clinical test delivery. It performs these services at its clinical laboratory improvement amendments (CLIA) lab
Its active pharmaceutical ingredients (API) services and chemical development are suitable for all stages of drug development, including small molecules, potent and cytotoxic compounds and peptides
The company also provides pharmaceutical development for optimising clinical candidates and manufacturing drug product for all phases of clinical trial supply
Almac’s analytical services deliver comprehensive solutions supporting drug substance and product development programmes.
Its clinical services include designing and providing blinding, packaging and logistics services for global clinical trials; incorporating leading technologies; and efficient solutions through experienced supply chain management.
The company’s clinical technologies provide randomisation and trial supply management, electronic clinical outcome assessments (eCOA), patient alerts and reminders, data integration and biostatistical consulting services
Almac’s commercial services offer manufacturing and packaging solutions to support commercial product launches.
Almac Group has experience in all phases of development, including pre-clinical, Phase I-IV, commercial and non-commercial
Almac Group is an international company that is privately owned and has organically grown for more than 40 years, employing in excess of 4,500 highly skilled personnel.
The company is headquartered in Craigavon, Northern Ireland, and has operations in Ireland, the US and Asia.
Almac Group’s global employee base ensures all projects are handled as effectively and efficiently as possible.
Almac combines global reach with local expertise to provide expert, innovative and high-quality service to more than 600 pharmaceutical and biotech companies worldwide.
Almac Group also offers expert global distribution capabilities, with 60 depots around the world, including China, India, Peru, Brazil, Mexico, Russia and Canada.
Almac Group understands each individual client’s needs are unique and prides itself on adapting its services.
The Group partners with a diverse customer base, including pharmaceutical, biotech, contract research organisations (CRO), academia and virtual organisations guaranteeing the stability of the company and building greater expertise and experience.
In addition, it possesses a wealth of experience across all therapeutic areas, including oncology, immunology, infectious diseases, pulmonary and respiratory diseases, gastroenterology, central nervous system and neurology.
Almac Group is a financially stable company with no venture capital investment and is committed to the long term development and growth of the organisation. All profit is reinvested into the business to continually improve its innovation, technology, capabilities and people. Group turnover is currently $½ billion and is experience consistent growth year on year.
The Almac Group’s vision clearly positions the organisation within the industry, aiming to be a leader in the generation of superior solutions for the advancement of human health.
The company’s core values define Almac’s fundamental set of principles and beliefs, focusing on:
• Outstanding quality
• Inspirational people
• Superlative customer focus
• Exceptional innovation
• Sustainable financial performance
UK (Global Headquarters)
20 Seagoe Industrial Estate
T: +44 (0) 283 833 2200
F: +44 (0) 283 833 2299